Value of gadoxetate biliary transit time in determining hepatocyte function

Jianwei Wu, Hui Li, Yuning Lin, Ziqian Chen, Qun Zhong, Hong Gao, Liyuan Fu, Kumar Sandrasegaran

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective: To determine if transit time for excretion of gadoxetate into major bile ducts and duodenum correlates with clinical models of hepatocellular function. Methods: This retrospective research was approved by the Institutional Review Board with waiver of informed consent. Search of the radiology database from January 1, 2013 to March 4, 2014 revealed 84 patients with chronic liver disease (65 males, mean age 47 years). Eighteen control subjects with no known liver disease or risk factors were also enrolled for analysis (9 males, mean age 43 years). MRI was performed with hepatobiliary phases at 10, 15, 20, and 25 min after injection of 0.025 mmol/kg of gadoxetate (Primovist, Bayer HealthCare, Shanghai, China). The time of excreted contrast appearing in the biliary tree and in the duodenum was recorded. Linear trend analysis was performed to determine the relationship between excretion time and hepatic function. Results: The patient cohort was stratified by Child-Pugh classification (A, B, and C with n = 53, 27, and 4, respectively). Arrival of gadoxetate in the gall bladder at 10-min hepatobiliary phase was seen in 87% of control group and 45% of Child-Pugh A group (p = 0.02). There was no difference between these groups for later hepatobiliary phases. The arrival of biliary contrast in the right hepatic duct, common bile duct, and gall bladder were significantly earlier in the Child-Pugh A group compared to the Child-Pugh B/C group at all hepatobiliary phases after 10 min (p 

Original languageEnglish (US)
Pages (from-to)95-101
Number of pages7
JournalAbdominal Imaging
Volume40
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Hepatocytes
Duodenum
Liver Diseases
Urinary Bladder
Common Hepatic Duct
Research Ethics Committees
Common Bile Duct
Biliary Tract
Bile Ducts
Informed Consent
Radiology
China
Chronic Disease
Databases
Delivery of Health Care
Control Groups
Injections
Research

Keywords

  • Cirrhosis
  • Gadoxetate
  • Hepatobiliary phase
  • Magnetic resonance imaging

ASJC Scopus subject areas

  • Gastroenterology
  • Urology
  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology
  • Medicine(all)

Cite this

Value of gadoxetate biliary transit time in determining hepatocyte function. / Wu, Jianwei; Li, Hui; Lin, Yuning; Chen, Ziqian; Zhong, Qun; Gao, Hong; Fu, Liyuan; Sandrasegaran, Kumar.

In: Abdominal Imaging, Vol. 40, No. 1, 01.01.2015, p. 95-101.

Research output: Contribution to journalArticle

Wu, Jianwei ; Li, Hui ; Lin, Yuning ; Chen, Ziqian ; Zhong, Qun ; Gao, Hong ; Fu, Liyuan ; Sandrasegaran, Kumar. / Value of gadoxetate biliary transit time in determining hepatocyte function. In: Abdominal Imaging. 2015 ; Vol. 40, No. 1. pp. 95-101.
@article{839e25c70c304852a713720f67e79194,
title = "Value of gadoxetate biliary transit time in determining hepatocyte function",
abstract = "Objective: To determine if transit time for excretion of gadoxetate into major bile ducts and duodenum correlates with clinical models of hepatocellular function. Methods: This retrospective research was approved by the Institutional Review Board with waiver of informed consent. Search of the radiology database from January 1, 2013 to March 4, 2014 revealed 84 patients with chronic liver disease (65 males, mean age 47 years). Eighteen control subjects with no known liver disease or risk factors were also enrolled for analysis (9 males, mean age 43 years). MRI was performed with hepatobiliary phases at 10, 15, 20, and 25 min after injection of 0.025 mmol/kg of gadoxetate (Primovist, Bayer HealthCare, Shanghai, China). The time of excreted contrast appearing in the biliary tree and in the duodenum was recorded. Linear trend analysis was performed to determine the relationship between excretion time and hepatic function. Results: The patient cohort was stratified by Child-Pugh classification (A, B, and C with n = 53, 27, and 4, respectively). Arrival of gadoxetate in the gall bladder at 10-min hepatobiliary phase was seen in 87{\%} of control group and 45{\%} of Child-Pugh A group (p = 0.02). There was no difference between these groups for later hepatobiliary phases. The arrival of biliary contrast in the right hepatic duct, common bile duct, and gall bladder were significantly earlier in the Child-Pugh A group compared to the Child-Pugh B/C group at all hepatobiliary phases after 10 min (p ",
keywords = "Cirrhosis, Gadoxetate, Hepatobiliary phase, Magnetic resonance imaging",
author = "Jianwei Wu and Hui Li and Yuning Lin and Ziqian Chen and Qun Zhong and Hong Gao and Liyuan Fu and Kumar Sandrasegaran",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/s00261-014-0200-3",
language = "English (US)",
volume = "40",
pages = "95--101",
journal = "Abdominal Imaging",
issn = "0942-8925",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Value of gadoxetate biliary transit time in determining hepatocyte function

AU - Wu, Jianwei

AU - Li, Hui

AU - Lin, Yuning

AU - Chen, Ziqian

AU - Zhong, Qun

AU - Gao, Hong

AU - Fu, Liyuan

AU - Sandrasegaran, Kumar

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Objective: To determine if transit time for excretion of gadoxetate into major bile ducts and duodenum correlates with clinical models of hepatocellular function. Methods: This retrospective research was approved by the Institutional Review Board with waiver of informed consent. Search of the radiology database from January 1, 2013 to March 4, 2014 revealed 84 patients with chronic liver disease (65 males, mean age 47 years). Eighteen control subjects with no known liver disease or risk factors were also enrolled for analysis (9 males, mean age 43 years). MRI was performed with hepatobiliary phases at 10, 15, 20, and 25 min after injection of 0.025 mmol/kg of gadoxetate (Primovist, Bayer HealthCare, Shanghai, China). The time of excreted contrast appearing in the biliary tree and in the duodenum was recorded. Linear trend analysis was performed to determine the relationship between excretion time and hepatic function. Results: The patient cohort was stratified by Child-Pugh classification (A, B, and C with n = 53, 27, and 4, respectively). Arrival of gadoxetate in the gall bladder at 10-min hepatobiliary phase was seen in 87% of control group and 45% of Child-Pugh A group (p = 0.02). There was no difference between these groups for later hepatobiliary phases. The arrival of biliary contrast in the right hepatic duct, common bile duct, and gall bladder were significantly earlier in the Child-Pugh A group compared to the Child-Pugh B/C group at all hepatobiliary phases after 10 min (p 

AB - Objective: To determine if transit time for excretion of gadoxetate into major bile ducts and duodenum correlates with clinical models of hepatocellular function. Methods: This retrospective research was approved by the Institutional Review Board with waiver of informed consent. Search of the radiology database from January 1, 2013 to March 4, 2014 revealed 84 patients with chronic liver disease (65 males, mean age 47 years). Eighteen control subjects with no known liver disease or risk factors were also enrolled for analysis (9 males, mean age 43 years). MRI was performed with hepatobiliary phases at 10, 15, 20, and 25 min after injection of 0.025 mmol/kg of gadoxetate (Primovist, Bayer HealthCare, Shanghai, China). The time of excreted contrast appearing in the biliary tree and in the duodenum was recorded. Linear trend analysis was performed to determine the relationship between excretion time and hepatic function. Results: The patient cohort was stratified by Child-Pugh classification (A, B, and C with n = 53, 27, and 4, respectively). Arrival of gadoxetate in the gall bladder at 10-min hepatobiliary phase was seen in 87% of control group and 45% of Child-Pugh A group (p = 0.02). There was no difference between these groups for later hepatobiliary phases. The arrival of biliary contrast in the right hepatic duct, common bile duct, and gall bladder were significantly earlier in the Child-Pugh A group compared to the Child-Pugh B/C group at all hepatobiliary phases after 10 min (p 

KW - Cirrhosis

KW - Gadoxetate

KW - Hepatobiliary phase

KW - Magnetic resonance imaging

UR - http://www.scopus.com/inward/record.url?scp=84942608004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942608004&partnerID=8YFLogxK

U2 - 10.1007/s00261-014-0200-3

DO - 10.1007/s00261-014-0200-3

M3 - Article

C2 - 25056714

AN - SCOPUS:84942608004

VL - 40

SP - 95

EP - 101

JO - Abdominal Imaging

JF - Abdominal Imaging

SN - 0942-8925

IS - 1

ER -